BALDINI, CHIARA
 Distribuzione geografica
Continente #
NA - Nord America 10.877
EU - Europa 4.378
AS - Asia 2.203
AF - Africa 355
SA - Sud America 102
OC - Oceania 46
Continente sconosciuto - Info sul continente non disponibili 8
Totale 17.969
Nazione #
US - Stati Uniti d'America 10.529
IT - Italia 1.355
CN - Cina 1.122
SE - Svezia 980
BG - Bulgaria 581
SG - Singapore 426
DE - Germania 360
GB - Regno Unito 311
CA - Canada 308
VN - Vietnam 255
FI - Finlandia 165
CI - Costa d'Avorio 151
NL - Olanda 121
TR - Turchia 117
IN - India 104
UA - Ucraina 103
NG - Nigeria 101
HK - Hong Kong 86
FR - Francia 85
SN - Senegal 81
AT - Austria 61
RU - Federazione Russa 49
CH - Svizzera 46
AU - Australia 44
BR - Brasile 44
BE - Belgio 41
ES - Italia 33
MX - Messico 32
JP - Giappone 28
CO - Colombia 19
KR - Corea 17
PL - Polonia 16
RO - Romania 14
GR - Grecia 13
TW - Taiwan 13
IE - Irlanda 10
AR - Argentina 9
MA - Marocco 9
EC - Ecuador 8
EU - Europa 8
CL - Cile 7
PE - Perù 7
PT - Portogallo 7
IL - Israele 6
IR - Iran 5
NO - Norvegia 5
AM - Armenia 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
DZ - Algeria 4
EG - Egitto 4
HR - Croazia 4
MY - Malesia 4
BO - Bolivia 3
LB - Libano 3
SA - Arabia Saudita 3
UY - Uruguay 3
GT - Guatemala 2
HU - Ungheria 2
ID - Indonesia 2
LK - Sri Lanka 2
MD - Moldavia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PH - Filippine 2
RE - Reunion 2
SK - Slovacchia (Repubblica Slovacca) 2
BF - Burkina Faso 1
BJ - Benin 1
FK - Isole Falkland (Malvinas) 1
GL - Groenlandia 1
IQ - Iraq 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MN - Mongolia 1
PA - Panama 1
PR - Porto Rico 1
PY - Paraguay 1
RS - Serbia 1
SI - Slovenia 1
TH - Thailandia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 17.969
Città #
Woodbridge 1.624
Ann Arbor 1.125
Houston 1.024
Fairfield 957
Chandler 897
Sofia 580
Ashburn 549
Beijing 427
Seattle 427
New York 400
Wilmington 375
Cambridge 327
Milan 325
Princeton 276
Ottawa 261
Lawrence 233
Medford 216
Nanjing 163
Serra 152
Abidjan 151
Jacksonville 141
Des Moines 137
Florence 135
Singapore 132
Izmir 108
Dearborn 101
Lagos 101
Dong Ket 95
Bremen 84
London 84
Dakar 81
San Diego 69
Boardman 67
Hong Kong 67
Redwood City 57
Vienna 56
Ogden 55
Pisa 52
Pune 52
Nanchang 50
Rome 49
Frankfurt am Main 45
Falls Church 42
Lancaster 39
Kunming 38
Bern 36
Hefei 36
Shenyang 36
Hebei 34
Boulder 33
Shanghai 32
Jüchen 31
Amsterdam 29
Marseille 29
Brussels 27
Jiaxing 26
Los Angeles 25
Changsha 24
Guangzhou 23
Tianjin 20
Norwalk 19
Hangzhou 17
Phoenix 16
Trani 16
Düsseldorf 15
Indiana 14
Jinan 14
Vancouver 14
Melbourne 13
Warsaw 13
Leeuwarden 12
Maastricht 12
Chongqing 11
Fuzhou 11
Leuven 11
Livorno 11
Palermo 11
Washington 11
Houten 10
Madrid 10
Montecatini Terme 10
Wuhan 10
Altopascio 9
Barcelona 9
Dublin 9
Duncan 9
Genoa 9
Grafing 9
Redmond 9
Zhengzhou 9
Arezzo 8
Chengdu 8
Helsinki 8
Leeds 8
Saint Petersburg 8
Sittard 8
Taipei 8
Bari 7
Cascina 7
Council Bluffs 7
Totale 13.297
Nome #
Sjögren syndrome 922
IN THE CHRONIC MYELOID LEUKEMIA THE SALIVARY PROTEOMICS RECAPITULATES SOME ASPECTS OF THE LEUKEMIC STEM CELL. LA CELLULA STAMINALE LEUCEMICA E LA PROTEOMICA SALIVARE: IL MODELLO DELLA LEUCEMIA MIELOIDE CRONICA 158
Classification criteria 142
Correspondence between salivary proteomic pattern and clinical course in primary Sjogren syndrome and non-Hodgkin's lymphoma: a case report 141
A proposal of simple calculation (ERI calculator) to predict the early response to TNF-a blockers therapy in rheumatoid arthritis 140
Fibronectin gene polymorphisms are associated with the development of B-cell lymphoma in type II mixed cryoglobulinemia. 137
Anti-Sm and anti-RNP antibodies 130
Gross Cystic Disease Fluid Protein-15(GCDFP-15)/Prolactin-Inducible Protein (PIP) as Functional Salivary Biomarker for Primary Sjögren's Syndrome 130
[Churg-Strauss vasculitis and idiopathic hypereosinophyl syndrome: role of molecular biology in the differential diagnosis of hypereosinophyl syndrome] 129
TCR REARRANGEMENTS ARE NOT ENOUGH FOR DISTINGUISHING THE CHURG-STRAUSS SYNDROME FROM THE HYPEREOSINOPHILIC SYNDROME 123
Behçet's disease: features of neurological involvement in a dedicated centre in Italy. 122
Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients 120
Skin manifestations and sjögren’s syndrome 118
Impact of joint involvement on patients reported outcomes in systemic lupus erythematosus. 118
Efficacy and safety of rituximab in HCV-related mixed cryoglobulinemia 117
A Clinical Prediction Rule for Lymphoma Development in Primary Sjogren's Syndrome 117
In vivo confocal scanning laser microscopy in patients with primary Sjögren's syndrome: A monocentric experience. 117
Clinical manifestations and treatment of Churg-Strauss syndrome 116
Classification criteria for Sjogren's syndrome: A critical review. 114
Classification criteria for Sjogren's syndrome: A critical review. 114
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 113
Muscular vasculitis confined to lower limbs: description of two case reports and a review of the literature 113
Discontinuation rates and timing of antimalarial drugs in primary Sjögren's syndrome. 111
Occurrence of organ-specific and systemic autoimmune diseases among the first- and second-degree relatives of Caucasian patients with connective tissue diseases: report of data obtained through direct patient interviews 111
Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. 110
Mucocutaneous manifestations of Sjögren's Syndrome 109
Minor salivary gland biopsy and Sjögren's syndrome: comparative analysis of biopsies among different Italian rheumatologic centers 109
Churg-Strauss vasculitis and idiopathic hypereosinophyl syndrome: role of molecular biology in the differential diagnosis of hypereosinophyl syndrome 108
Treatment of chronic hepatitis C infection with cryoglobulinemia. 108
Skin manifestations and cryoglobulinemia 108
Occurrence of hashimoto thyroiditis among the first- and second-degree relatives of systemic lupus erythematosus patients with Hashimoto thyroiditis 108
Analysis of the evolution of UCTD to defined CTD after a long-term follow-up. 107
null 107
null 107
Is GRP78/BiP a potential salivary biomarker in patients with rheumatoid arthritis? 105
Proteomic diagnosis of Sjögren's syndrome 105
TNF-alpha inhibitors in Systemic Lupus Erythematosus. A case report and a systematic literature review 104
null 104
Undifferentiated connective tissue diseases (UCTD) 103
Changes of flow mediated dilation in pregnant patients with systemic autoimmune diseases 103
null 102
Artrite reumatoide e analisi proteomica della saliva 101
Alteration of microcirculation is a hallmark of very early systemic sclerosis patients: a laser speckle contrast analysis. 101
Proteome analysis of whole saliva: a new tool for rheumatic diseases--the example of Sjögren's syndrome. 101
miRNA-mediated regulation of Mucin-type O-Glycosylation pathway: a putative mechanism of salivary gland dysfunction in Sjögren's syndrome 101
Impact of joint involvement on patients reported outcomes in systemic lupus erythematosus 100
A Clinical prediction rule for lymphoma development in primary and secondary Sjogren’s syndrome. 99
Emerging trends in Sjögren's syndrome: basic and translational research. 98
Rhupus syndrome: Assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. 98
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 97
Proteomics approach as a tool for salivary fingerprint characterization able to discriminate different Sjögren’s syndrome phenotype. 96
null 94
null 94
Proteomic analysis of the saliva: A clue for understanding primary from secondary Sjogren's syndrome? 94
The economic impact of gout: a systematic literature review. 93
Outcome of pregnancy in Italian patients with primary Sjögren syndrome 93
Current Concepts on Classification Criteria and Disease Status Indexes in Sjögren’s Syndrome 92
null 92
null 92
null 92
Primary Sjogren's Syndrome: clinical and serological feature of a single centre [Sindrome di Sjogren primitiva: Descrizione clinica e sierologica di una casistica monocentrica] 91
null 91
null 91
Undifferentiated connective tissue diseases in 2004 90
Minor salivary gland biopsy and Sjögren's syndrome: comparative analysis of biopsies among different Italian rheumatologic centers. 90
The association of Sjögren syndrome and autoimmune thyroid disorders 90
MALDI-TOF and SELDI-TOF analysis: "tandem" techniques to identify potential biomarker in fibromyalgia. [MALDI-TOF e SELDI-TOF: due tecniche “tandem” per l’individuazione di potenziali biomarker nella fibromialgia] 90
Cystatin S-a candidate biomarker for severity of submandibular gland involvement in Sjögren's syndrome 90
A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren's syndrome. 89
null 89
Detection of potential markers of primary fibromyalgia syndrome in human saliva 89
Specific proteins identified in whole saliva from patients with diffuse systemic sclerosis 88
Biomarkers for Sjögren's syndrome 88
LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus 87
Updates on Sjögren's syndrome: from proteomics to protein biomarkers 87
Omalizumab: a novel steroid sparing agent in eosinophilic granulomatosis with polyangiitis? 86
Occurrence of organ-specific and systemic autoimmune diseases among the first- and second-degree relatives of Caucasian patients with connective tissue diseases: report of data obtained through direct patient interviews 86
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES 86
null 86
null 85
Eosinophilic granulomatosis with polyangiitis and laryngeal involvement: Review of the literature and a cross-sectional prospective experience 85
Phenotyping multiple subsets in Sjögren’s syndrome: a salivary proteomic SWATH-MS approach towards precision medicine 84
null 83
Proteomic analysis of saliva: a unique tool to distinguish primary Sjogren's syndrome from secondary Sjogren's syndrome and other sicca syndromes 82
Ultrasound imaging for the rheumatologist. XXIII. Sonographic evaluation of hand joint involvement in primary Sjogren's Syndrome 82
Sjogren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren's syndrome, derived from an analysis of a cohort of Italian patients 82
Mikulicz's disease: a long-term follow-up case report. 81
null 81
Skin involvment and outcome measures in systemic autoimmune diseases 80
Alteration of microcirculation is a hallmark of very early systemic sclerosis patients: a laser speckle contrast analysis. 80
Large- and small-vessel vasculitis: a critical digest of the \2010-2011 literature. 79
The value of outcome measures in autoimmune rheumatic diseases 79
Saliva as an ideal milieu for emerging diagnostic approaches in primary Sjögren's syndrome. 79
Classification criteria in Sjögren’s syndrome 79
How HCV has changed the approach to mixed cryoglobulinemia 78
null 78
null 77
Patterns of inflammation and dysfunction in pSS: identification of proteomic salivary biomarkers correlated with different disease phenotypes. 77
null 76
Association of psoriasin (S100A7) with clinical manifestations of systemic sclerosis: Is its presence in whole saliva a potential predictor of pulmonary involvement? 75
Totale 10.774
Categoria #
all - tutte 53.979
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.979


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.339 0 280 132 184 251 314 262 196 217 217 213 73
2020/20211.444 78 58 49 61 106 178 77 104 173 112 112 336
2021/20222.623 47 180 39 168 473 377 98 136 134 97 161 713
2022/20233.416 437 428 247 287 407 379 41 237 575 50 263 65
2023/20242.595 239 241 278 178 387 504 139 71 54 73 129 302
2024/202585 74 11 0 0 0 0 0 0 0 0 0 0
Totale 18.697